Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms ARD-2065 |
Target |
Action degraders |
Mechanism AR degraders(Androgen Receptor degraders) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC43H44F3N9O5 |
InChIKeyHNKPULWLPWUHNX-FDLYHPRCSA-N |
CAS Registry2632305-80-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Prostate Carcinoma | Preclinical | United States | Oncopia Therapeutics, Inc.Startup | 29 Jun 2023 |
Advanced Prostate Carcinoma | Preclinical | United States | 29 Jun 2023 |